siRNA Treatment Slashes Viral Gene Expression by 80%
News Mar 31, 2017 | Original story from Tomsk Polytechnic University (TPU)
Scientists from Tomsk Polytechnic University together with their colleagues from St. Petersburg and London published a scientific article on new treatment methods against Swine influenza (H1N1 Flu). The obtained results can be applied to a new delivery system of antiviral drugs to fight with various influenza types.
The research was conducted by scientists from the Novel Dosage Laboratory, RASA Center at TPU, Pavlov First Saint Petersburg State Medical University, Research Institute of Influenza of Ministry of Healthcare of the Russian Federation and Queen Mary University of London School of Engineering and Materials Science. Scientists from Gorbacheva Research Institute of Pediatric Hematology and Transplantation also took an active part in the research.
A new method to fight influenza A (H1N1) virus is focused on training our body to produce interferons (proteins that make our body immune to the virus) faster.
TPU scientists suggest activating cell immune system with hybrid spherical microcontainers that contain antiviral RNAs (Ribonucleic Acids).
“We used small interfering RNA, which interact with matrix RNA (mRNA) of the influenza virus. This leads to degradation of “viral” RNA, preventing its translation on ribosomes into a protein encoded by it, thereby reducing the viral gene expression,” says one of the main co-authors of the research Alexander Timin, a JRF of the Novel Dosage Laboratory at Tomsk RASA Center.
The delivery of microcontainers with small interfering RNA is ensured within the human body through respiratory tract - nasal sinuses. In the sinus cavity the microcontainers degrade and release RNA into cells, which results in the transfection and therefore enhances immunity against influenza virus.
“For the first time we have developed an approach of efficient matrix RNA delivery through encapsulation into new hybrid microcarriers obtained by integration of LbL technique and sol-gel method. Three types of siRNA against influenza A (H1N1) virus infection were encapsulated in hybrid carriers. Such hybrid carriers have several advantages: low toxicity, efficient intracellular delivery and protection of siRNA against premature degradation prior to reaching the target cells. The results obtained may be used for new antiviral delivery that will further contribute to efficient fight with influenza virus,” the article reports.
According to scientists, the first laboratory test showed that such interaction results in an 80% drop of virus proteins.
Academic Redesigns FDA-Approved MabThera to Treat ALSNews
Researchers have redesigned a portion of the FDA-apporved MabThera for better-targeted treatment of ALS.READ MORE
Liver Fluke Granulin Structural Fold Provides Wound Healing OpportunityNews
Researchers can now mass produce wound-healing peptides isolated from the spit of the human parasitic liver fluke, a worm that causes liver cancer and kills 26,000 people in Thailand each year.READ MORE
Biogen's MS Drug FAMPYRA Granted Standard Marketing Authorization in EUNews
Biogen's drug FAMPYRA improves walking for MS sufferers and has been granted standard marketing authorization.READ MORE
Comments | 0 ADD COMMENT
2nd Partnership in Biocontrol, Biostimulants & Microbiome Congress
Nov 02 - Nov 03, 2017
5th Annual Outscourcing in Clinical Trials Nordics 2017
Oct 10 - Oct 11, 2017
EMBL Course: Analysis of Non-Coding RNAs: quaerite et invenietis
Sep 09 - Sep 15, 2017